Anti-Tau (phospho S324) 抗体 [EPR2457(2)] (ab109401)

製品の概要

• 製品名Anti-Tau (phospho S324) antibody [EPR2457(2)]
  Tau 一次抗体 製品一覧
• 製品の詳細
  Rabbit monoclonal [EPR2457(2)] to Tau (phospho S324)
• 特異性ab109401 only detects Tau phosphorylated at Serine 324.
• アプリケーション適用あり: WB, IP, ICC/IFmore details
  適用なし: Flow Cyt or IHC-P
• 種交差性
  交差種: Mouse, Rat, Human
  
• 免疫原

  Phospho specific peptide corresponding to residues surrounding Serine 324 of Human Tau.

• ポジティブ･コントロール
  • SH-SY5Y cells and cell lysates.
• 特記事項

  This product is a recombinant rabbit monoclonal antibody.

  Produced using Abcam’s RabMAb^® technology. RabMAb^® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

  A trial size is available to purchase for this antibody.

製品の特性

• 製品の状態Liquid
• 保存方法Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
• バッファーPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
• 精製度Tissue culture supernatant
• ポリ/モノモノクローナル
• クローン名EPR2457(2)
• アイソタイプIgG
• 研究分野
  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Alzheimer's disease
  • Tangles & Tau

  • Signal Transduction
  • Cytoskeleton / ECM
  • Cytoskeleton
  • Microtubules
  • MT Associated Proteins
  • Tau

  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Other

  • Neuroscience
  • Cell Type Marker
  • Neuron marker
  • Axon marker

関連製品

• Related Products
  • Human Tau ELISA Kit (ab210972)

アプリケーション

ターゲット情報

• 機能Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
• 組織特異性Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
• 関連疾患Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
  Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
  Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
  Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
  Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
• 配列類似性Contains 4 Tau/MAP repeats.
• 発生段階Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
• ドメインThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
• 翻訳後修飾Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
  Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
  Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
• 細胞内局在Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.

• Target information above from: UniProt accession P10636 The UniProt Consortium
  The Universal Protein Resource (UniProt) in 2010
  Nucleic Acids Res. 38:D142-D148 (2010) .

  Information by UniProt
• 参照データベース
  • Entrez Gene: 4137 Human
  • Entrez Gene: 17762 Mouse
  • Entrez Gene: 29477 Rat
  • Omim: 157140 Human
  • SwissProt: P10636 Human
  • SwissProt: P10637 Mouse
  • SwissProt: P19332 Rat
  • Unigene: 101174 Human

  • Unigene: 1287 Mouse
  • Unigene: 2455 Rat

  see all
• 製品の状態There are 9 isoforms produced by alternative splicing.
• 別名
  • AI413597 antibody
  • AW045860 antibody
  • DDPAC antibody

  • FLJ31424 antibody
  • FTDP 17 antibody
  • G protein beta1/gamma2 subunit interacting factor 1 antibody
  • MAPT antibody
  • MAPTL antibody
  • MGC134287 antibody
  • MGC138549 antibody
  • MGC156663 antibody
  • Microtubule associated protein tau antibody
  • Microtubule associated protein tau isoform 4 antibody
  • Microtubule-associated protein tau antibody
  • MSTD antibody
  • Mtapt antibody
  • MTBT1 antibody
  • MTBT2 antibody
  • Neurofibrillary tangle protein antibody
  • Paired helical filament tau antibody
  • Paired helical filament-tau antibody
  • PHF tau antibody
  • PHF-tau antibody
  • PPND antibody
  • PPP1R103 antibody
  • Protein phosphatase 1, regulatory subunit 103 antibody
  • pTau antibody
  • RNPTAU antibody
  • TAU antibody
  • TAU_HUMAN antibody
  • Tauopathy and respiratory failure, included antibody

  see all